Hematology Oncology 16 (2), 159163
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
Hsieh, M., Lee, C., Chueh, H., Chang, G., Huang, H., Lin, Y., & Pang, J
If serum values were decisive, even patients with neurological involvement could suffice with the maintenance dose of one injection every two months after the initial loading dose